|
Lilly Acquires ImClone Systems In $6.5B Transaction (PharmaceuticalOnline)
Eli Lilly and Company and ImClone Systems Inc. recently announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5B.
us.rd.yahoo.com
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction (PR Newswire via Yahoo! Finance)
Eli Lilly and Company and ImClone Systems Inc. today announced that the boards of directors of both companies have approved a definitive merger agreement under which Lilly will acquire ImClone through an all cash tender offer of $70.00 per share, or approximately $6.5 billion.
us.rd.yahoo.com
ALIMTA given FDA nod for first-line treatment of non-small cell lung cancer (CancerFacts.com)
INDIANAPOLIS – Oct. 2, 2008 (cancerfacts.com) – The FDA has approved premetrexed (ALIMTA®) in combination with cisplatin for the first-line treatment of a specific type of locally-advanced non-small cell lung cancer.
us.rd.yahoo.com
Eli Lilly: Alimta receives US green light for lung cancer (Pharmaceutical Business Review)
Alimta has received US approval for use as a first-line therapy in locally advanced and metastatic non-small cell lung cancer in combination with cisplatin. This third FDA approval for Alimta follows its prominent use in patients with non-squamous carcinoma cell histology and highlights the shift towards a more tailored approach for lung cancer therapy.
us.rd.yahoo.com
My Pharmiweb.com (PharmiWeb)
INDIANAPOLIS, Sept 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ Eli Lilly and Company (NYSE: LLY) announced today it received approval from the U.S. Food and Drug Administration (FDA) for the use of ALIMTA(R) (pemetrexed for injection), in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer (NSCLC), for patients with ...
us.rd.yahoo.com
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval (PR Newswire via Yahoo! Finance)
Eli Lilly and Company announced today it received approval from the U.S. Food and Drug Administration for the use of ALIMTA® , in combination with cisplatin, in the first-line treatment of locally-advanced and metastatic non-small cell lung cancer , for patients with nonsquamous histology.
us.rd.yahoo.com
|
